Author

Chudy I. Nduaka 1

1 Pfizer Inc,Collegeville, PA,United States

ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE ULCERATIVE COLITIS PROGRAMME FOR TOFACITINIB

Bruce E. Sands, Millie D. Long, Leonard Baidoo, Walter Reinisch, Julian Panés, Chudy I. Nduaka, Arif Soonasra, Ronald D. Pedersen, Nervin Lawendy, Gary Chan, Gary S. Friedman, Chinyu Su

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES

Uma Mahadevan, Daniel C. Baumgart, Marla C. Dubinsky, Nervin Lawendy, Gary S. Friedman, Gauree G. Konijeti, Hans Peter Gröchenig, Thomas V Jones, Amy Marren, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

TOFACITINIB 15 MILLIGRAMS TWICE DAILY FOR PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM 8-WEEK INDUCTION STUDIES OCTAVE INDUCTION 1 & 2

David T. Rubin, Satoshi Motoya, Stefan Schreiber, Daniel Quirk, Chudy I. Nduaka, Nervin Lawendy, Deborah A. Woodworth, Wenjin Wang, Chinyu Su, Peter D. R. Higgins

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY

Gary R. Lichtenstein, Edward V Loftus Jr, Stuart Bloom, Nervin Lawendy, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 4.9 YEARS OF TREATMENT

Gary R. Lichtenstein, Edward V. Loftus Jr., Stuart Bloom, Nervin Lawendy, Gary Chan, Gary S. Friedman, Haiying Zhang, Wenjin Wang, Andrew J. Thorpe, Chudy I. Nduaka, Chinyu Su

Item 1 - 6 / 6
1
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK